Topomer-CoMFA Study of Tricyclic Azepine Derivatives-EGFR Inhibitors |
Chung, Jae-Yoon
(Computational Science Center, Future Fusion Technology Division, Korea Institute of Science and Technology)
Pasha, F.A. (Computational Science Center, Future Fusion Technology Division, Korea Institute of Science and Technology) Chung, Hwan-Won (Computational Science Center, Future Fusion Technology Division, Korea Institute of Science and Technology) Yang, Beom-Seok (Computational Science Center, Future Fusion Technology Division, Korea Institute of Science and Technology) Lee, Cheol-Ju (Computational Science Center, Future Fusion Technology Division, Korea Institute of Science and Technology) Oh, Jung-Soo (Computational Science Center, Future Fusion Technology Division, Korea Institute of Science and Technology) Moon, Myoung-Woon (Computational Science Center, Future Fusion Technology Division, Korea Institute of Science and Technology) Cho, Seung-Joo (Computational Science Center, Future Fusion Technology Division, Korea Institute of Science and Technology) Cho, Art E. (Department of Biotechnology and Bioinformatics, Korea University) |
1 | Sorrentino, B. P. Gene therapy to protect haematopoietic cells from cytotoxic cancer drugs. Nat Rev Cancer 2:431-441 (2002) DOI ScienceOn |
2 | Hubbard, S. R. & Till, J. H. Protein tyrosine kinase structure and function. Annual Review of Biochemistry 69:373-398 (2000) DOI ScienceOn |
3 | Janmaat, M. L. & Giaccone, G. Small-molecule epidermal growth factor receptor tyrosine kinase inhibitors. Oncologist 8:576-586 (2003) DOI |
4 | Traxler, P. et al. Tyrosine kinase inhibitors: from rational design to clinical trials. Medicinal Research Reviews 21:499-512 (2001) DOI ScienceOn |
5 | Stamos, J., Sliwkowski, M. X. & Eigenbrot, C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem 277:46265-46272 (2002) DOI ScienceOn |
6 | Cramer, R. D. & Patterson, D. E. Further method of creating and rapidly searching a virtual library of potential molecules using validated molecular structural descriptors. United States. (2001) |
7 | Baselga, J. Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 7:2-8 (2002) |
8 | Lo, H-W., Hsu, S. C. & Hung, M. C. EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear translocalization. Breast Cancer Research and Treatment 95:211-218 (2006) DOI |
9 | Wold, S., Sjostrom, M. & Eriksson, L. PLS-regression: a basic tool of chemometrics. Chemometrics and Intelligent Laboratory Systems 58:109-130 (2001) DOI ScienceOn |
10 | Toschi, L. & Cappuzzo, F. Understanding the new genetics of responsiveness to epidermal growth factor receptor tyrosine kinase inhibitors. Oncologist 12:211-220 (2007) DOI ScienceOn |
11 | Smith Ii, L. et al. Novel tricyclic azepine derivatives: biological evaluation of pyrimido[4,5-b]-1,4-benzoxazepines, thiazepines, and diazepines as inhibitors of the epidermal growth factor receptor tyrosine kinase. Bioorganic & Medicinal Chemistry Letters 16:5102-5106 (2006) DOI ScienceOn |
12 | Cohen, P. Protein kinases-the major drug targets of the twenty-first century? Nature Reviews Drug Discovery 1:309-315 (2002) DOI ScienceOn |
13 | Cramer, R. D. Topomer CoMFA: A design methodology for rapid lead optimization. J Med Chem 46:374-388 (2003) DOI ScienceOn |
14 | Tripos Bookshelf 7.3. Tripos Inc. (1699) |
15 | Noble, M. E. M., Endicott, J. A. & Johnson, L. N. Protein kinase inhibitors: insights into drug design from structure. Sience 303:1800-1805 (2004) DOI |
16 | Cramer, R. D. & Jilek, R. J. Comparative field analysis (CoMFA) utilizing topomeric alignment of molecular fragments. United States. (2003) |
17 | Bush, B. L. & Nachbar, R. B. Sample-distance partial least squares: PLS optimized for many variables, with application to CoMFA. Journal of Computer-Aided Molecular Design 7:587-619 (1993) DOI |
18 | Kurup, A., Garg, R. & Hansch, C. Comparative QSAR study of tyrosine kinase inhibitors. Chem Rev 101:2573-2600 (2001) DOI ScienceOn |
19 | Dawson, J. P. et al. Epidermal growth factor receptor dimerization and activation require ligand-induced conformational changes in the dimer interface. Mol Cell Biol 25:7734-7742 (2005) DOI ScienceOn |
20 | Bridges, A. J. et al. Tyrosine kinase inhibitors. 8. an unusually steep structure-activity relationship for analogues of 4-(3-Bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor. J Med Chem 39:267-276 (1996) DOI ScienceOn |
21 | Jilek, R. J. & Cramer, R. D. Topomers: a validated protocol for their self-consistent generation. J Chem Inf Comput Sci 44:1221-1227 (2004) DOI ScienceOn |
22 | Katsman, A., Umezawa, K. & Bonavida, B. Reversal of resistance to cytotoxic cancer therapies: DHMEQ as a chemo-sensitizing and immuno-sensitizing agent. Drug Resistance Updates 10:1-12 (2007) DOI ScienceOn |